CD8A and melanoma: Ramirez-Montagut and coworkers observed increased survival upon DTA-1 application in their tumor models (BALB/c mice injected with RENCA cells and C57BL/6 mice inoculated with B16 melanoma cells), which required presence of CD4+ and CD8+ T cells.